Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro

Journal of Infectious Diseases

Volumn 176, Issue 1, 1997, Pages 265-268

  Merrill, Debra P ^b   Manion, Douglas J ^b   Chou, Ting Chao ^b   Hirsch, Martin S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; PHYTOHEMAGGLUTININ; PROTEINASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MONONUCLEAR CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; VIRUS ISOLATION;

EID: 0030970697     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517263     Document Type: Article

References (9)

1. Johnson VA, Merrill DP, Videler JA, et al. Two-drag combinations of zidovudine, didanosinc, and recombinant interferon-αA inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis 1991;164:646-55.
2. Shafer RW, Iversen AK, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC. Drag resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type I -infected subjects to zidovudine and didanosine combination therapy. J Infect Dis 1995;172:70-8.
3. 50 synergism, antagonism, low-dose risk, receptor-ligand binding and enzyme kinetics: a computer software for IBM-PC and manual. Cambridge, UK: Biosoft, 1989.
4. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism in chemotherapy. In: Chou TC, Rideout DC, ed. Synergism and antagonism in chemotherapy. New York: Academic Press, 1991:61-102.
5. Johnson VA. Evaluation of candidate anti-HIV agents in vitro. In: Walker BD, Aldovini A, ed. Techniques in HIV research. New York: Stockton Press, 1990:225-37.
6. Vacca JP, Dorsey BD, Schleif WA, et al. L-735,524: an orally bioavailable human immunodeficiency viras type 1 protease inhibitor. Proc Natl Acad Sci USA 1994;91:4096-100.
7. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995;345:952-5.
8. Rose RE, Gong YF, Greytok JA, et al. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci USA 1996;93:1648-53.
9. Deminie CA, Bechtold CM, Stock D, et al. Evaluation of reverse transcriptase and protease inhibitors in two-drag combinations against human immunodeficiency viras replication. Antimicrob Agents Chemother 1996;40:1346-51.